Last reviewed · How we verify

VIT-45 — Competitive Intelligence Brief

VIT-45 (VIT-45) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin D analog. Area: Immunology.

phase 3 Vitamin D analog Vitamin D receptor (VDR) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

VIT-45 (VIT-45) — American Regent, Inc.. VIT-45 is a vitamin D analog that enhances immune function and reduces inflammation through vitamin D receptor signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
VIT-45 TARGET VIT-45 American Regent, Inc. phase 3 Vitamin D analog Vitamin D receptor (VDR)
Dovonex CALCIPOTRIENE marketed Vitamin D Analog [EPC] Vitamin D3 receptor 1993-01-01
Alfarol 1.0 µg Alfarol 1.0 µg Eli Lilly and Company marketed Vitamin D analog Vitamin D receptor (VDR)
Hidroferol® Hidroferol® Hospital Universitario de Canarias marketed Vitamin D analog Vitamin D receptor (VDR)
Calcifediol Oral Product Calcifediol Oral Product OPKO Health, Inc. marketed Vitamin D analog Vitamin D receptor (VDR)
calcipotriene + clobetasol propionate calcipotriene + clobetasol propionate Leon Kircik, M.D. marketed Topical combination therapy (vitamin D analog + corticosteroid) Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
Xamiol® Gel Xamiol® Gel LEO Pharma marketed Combination topical agent (vitamin D analog + corticosteroid) Vitamin D receptor (VDR) and glucocorticoid receptor (GR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Vitamin D analog class)

  1. LEO Pharma · 2 drugs in this class
  2. Genzyme, a Sanofi Company · 2 drugs in this class
  3. National Cancer Institute, Naples · 2 drugs in this class
  4. OPKO Health, Inc. · 2 drugs in this class
  5. Joslin Diabetes Center · 1 drug in this class
  6. Kyowa Kirin, Inc. · 1 drug in this class
  7. Maimónides Biomedical Research Institute of Córdoba · 1 drug in this class
  8. Shanghai Jiao Tong University Affiliated Sixth People's Hospital · 1 drug in this class
  9. Shiraz University of Medical Sciences · 1 drug in this class
  10. St. Justine's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VIT-45 — Competitive Intelligence Brief. https://druglandscape.com/ci/vit-45. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: